Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00454286 | Stomach | GC | regulation of nitric oxide biosynthetic process | 12/1159 | 62/18723 | 3.62e-04 | 5.66e-03 | 12 |
GO:00602633 | Stomach | GC | regulation of respiratory burst | 6/1159 | 17/18723 | 3.80e-04 | 5.85e-03 | 6 |
GO:00098966 | Stomach | GC | positive regulation of catabolic process | 50/1159 | 492/18723 | 3.89e-04 | 5.97e-03 | 50 |
GO:00460316 | Stomach | GC | ADP metabolic process | 15/1159 | 90/18723 | 3.92e-04 | 5.99e-03 | 15 |
GO:00060966 | Stomach | GC | glycolytic process | 14/1159 | 81/18723 | 4.14e-04 | 6.27e-03 | 14 |
GO:00067576 | Stomach | GC | ATP generation from ADP | 14/1159 | 82/18723 | 4.71e-04 | 6.84e-03 | 14 |
GO:00160525 | Stomach | GC | carbohydrate catabolic process | 21/1159 | 154/18723 | 5.38e-04 | 7.55e-03 | 21 |
GO:00454295 | Stomach | GC | positive regulation of nitric oxide biosynthetic process | 9/1159 | 40/18723 | 6.17e-04 | 8.31e-03 | 9 |
GO:00434345 | Stomach | GC | response to peptide hormone | 43/1159 | 414/18723 | 6.20e-04 | 8.32e-03 | 43 |
GO:00068096 | Stomach | GC | nitric oxide biosynthetic process | 13/1159 | 76/18723 | 7.28e-04 | 9.50e-03 | 13 |
GO:19044075 | Stomach | GC | positive regulation of nitric oxide metabolic process | 9/1159 | 41/18723 | 7.48e-04 | 9.67e-03 | 9 |
GO:00060064 | Stomach | GC | glucose metabolic process | 23/1159 | 196/18723 | 2.39e-03 | 2.29e-02 | 23 |
GO:00224116 | Stomach | GC | cellular component disassembly | 42/1159 | 443/18723 | 3.99e-03 | 3.35e-02 | 42 |
GO:19016535 | Stomach | GC | cellular response to peptide | 35/1159 | 359/18723 | 5.29e-03 | 4.15e-02 | 35 |
GO:0051896 | Stomach | GC | regulation of protein kinase B signaling | 21/1159 | 185/18723 | 5.30e-03 | 4.15e-02 | 21 |
GO:00459953 | Stomach | GC | regulation of embryonic development | 10/1159 | 64/18723 | 5.67e-03 | 4.36e-02 | 10 |
GO:0070873 | Stomach | GC | regulation of glycogen metabolic process | 7/1159 | 36/18723 | 5.87e-03 | 4.44e-02 | 7 |
GO:004603411 | Stomach | CAG with IM | ATP metabolic process | 72/1050 | 277/18723 | 6.46e-29 | 1.72e-25 | 72 |
GO:000609111 | Stomach | CAG with IM | generation of precursor metabolites and energy | 86/1050 | 490/18723 | 1.45e-21 | 1.93e-18 | 86 |
GO:001598011 | Stomach | CAG with IM | energy derivation by oxidation of organic compounds | 64/1050 | 318/18723 | 1.96e-19 | 1.49e-16 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INSR | SNV | Missense_Mutation | | c.3652N>C | p.Asp1218His | p.D1218H | P06213 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
INSR | SNV | Missense_Mutation | | c.3556N>C | p.Glu1186Gln | p.E1186Q | P06213 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
INSR | SNV | Missense_Mutation | | c.2585N>C | p.Phe862Ser | p.F862S | P06213 | protein_coding | tolerated(0.88) | benign(0) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INSR | SNV | Missense_Mutation | | c.1889N>T | p.Ser630Leu | p.S630L | P06213 | protein_coding | deleterious(0.01) | possibly_damaging(0.459) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
INSR | SNV | Missense_Mutation | | c.487N>G | p.Ile163Val | p.I163V | P06213 | protein_coding | tolerated(0.06) | benign(0.123) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
INSR | SNV | Missense_Mutation | | c.2072C>G | p.Ser691Cys | p.S691C | P06213 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
INSR | insertion | In_Frame_Ins | novel | c.2752_2753insTGGCACAATCTCAGCTCACTGTAGCCTCCGCCTCCCGGGTTCAAG | p.Pro918delinsLeuAlaGlnSerGlnLeuThrValAlaSerAlaSerArgValGlnAla | p.P918delinsLAQSQLTVASASRVQA | P06213 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INSR | insertion | Frame_Shift_Ins | novel | c.1227_1228insAGAAAATGTATTGA | p.Leu412CysfsTer8 | p.L412Cfs*8 | P06213 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INSR | insertion | Frame_Shift_Ins | novel | c.1226_1227insGGGAAGTGACTGCCAAGTTGAAGTTAGGAGTG | p.Phe409LeufsTer17 | p.F409Lfs*17 | P06213 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INSR | deletion | Frame_Shift_Del | novel | c.2222delN | p.Phe741SerfsTer30 | p.F741Sfs*30 | P06213 | protein_coding | | | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | Metformin glycinate | | 22974412 |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201644 | INSULIN ZINC SUSP RECOMBINANT HUMAN | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201638 | INSULIN SUSP PROTAMINE ZINC PURIFIED PORK | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | ILORASERTIB | ILORASERTIB | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201639 | INSULIN ZINC SUSP BEEF | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201496 | INSULIN ASPART | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | BMS-754807 | BMS-754807 | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | CENISERTIB | CENISERTIB | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | Insulin-lispro | | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | AEW-541 | AEW-541 | |